國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Resistance to tyrosine kinase inhibitors

Focosi, Daniele.

Resistance to tyrosine kinase inhibitors

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Resistance to tyrosine kinase inhibitorsedited by Daniele Focosi.
其他作者:	Focosi, Daniele.
出版者:	Cham :Springer International Publishing :2016.
面頁冊數:	xiii, 188 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
標題:	Protein-tyrosine kinaseInhibitors.
電子資源:	http://dx.doi.org/10.1007/978-3-319-46091-8
ISBN:	9783319460918$q(electronic bk.)

Resistance to tyrosine kinase inhibitors
Resistance to tyrosine kinase inhibitors[electronic resource] /edited by Daniele Focosi. - Cham :Springer International Publishing :2016. - xiii, 188 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.102196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.4..

Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells -- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer -- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview -- Resistance to FLT3 Inhibitors -- Resistance to ALK inhibitors -- Resistance to Angiokinase Inhibitors -- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

ISBN: 9783319460918$q(electronic bk.)

Standard No.: 10.1007/978-3-319-46091-8doiSubjects--Topical Terms:

762681
Protein-tyrosine kinase
--Inhibitors.

LC Class. No.: RC271.P76

Dewey Class. No.: 615.798

Resistance to tyrosine kinase inhibitors
LDR:01900nmm a2200325 a 4500 001 499719
003 DE-He213
005 20161107143620.0
006 m d
007 cr nn 008maaau
008 170621s2016 gw s 0 eng d
020 $a 9783319460918$q(electronic bk.)
020 $a 9783319460901$q(paper)
024 7 $a 10.1007/978-3-319-46091-8 $2 doi
035 $a 978-3-319-46091-8
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.P76
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 615.798 $2 23
090 $a RC271.P76 $b R433 2016
245 0 0 $a Resistance to tyrosine kinase inhibitors $h [electronic resource] / $c edited by Daniele Focosi.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a xiii, 188 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.10
505 0 $a Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells -- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer -- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview -- Resistance to FLT3 Inhibitors -- Resistance to ALK inhibitors -- Resistance to Angiokinase Inhibitors -- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.
520 $a The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
650 0 $a Protein-tyrosine kinase $x Inhibitors. $3 762681
650 0 $a Drug resistance. $3 569293
650 1 4 $a Biomedicine. $3 273648
650 2 4 $a Cancer Research. $3 273660
700 1 $a Focosi, Daniele. $3 762680
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.4. $3 711051
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-46091-8
950 $a Biomedical and Life Sciences (Springer-11642)